"HexemBio's innovative approach recreates the embryonic environment where blood stem cells first form, avoiding the risks associated with traditional reprogramming methods like gene editing and cytokine treatments."
"The Synthetic Human Yolk Sac platform is designed to temporarily place a patient's own haematopoietic stem cells into a recreated developmental environment, enhancing their rejuvenation before returning them to the patient."
"Decline in haematopoietic stem cells with age is linked to weakened immunity and increased susceptibility to blood cancers, making this rejuvenation therapy crucial for improving patient outcomes."
HexemBio is pioneering a blood stem cell rejuvenation therapy that recreates the embryonic environment for blood stem cell formation. This approach avoids traditional methods like gene editing and chemical reprogramming, which can lead to instability. The technology uses a platform called the Synthetic Human Yolk Sac to temporarily place a patient's cells in a developmental microenvironment before returning them via IV infusion. The company has received FDA Orphan Drug Designation for its lead program targeting bone marrow transplants in blood cancer patients and has secured $10.4 million in seed funding.
Read at TNW | Health-Tech
Unable to calculate read time
Collection
[
|
...
]